# DOAC - Dosing Options in AntiCoagulation Prophylaxis

> **NCT07005024** · PHASE3 · RECRUITING · sponsor: **University of Vermont** · enrollment: 996 (estimated)

## Conditions studied

- Cancer
- VTE (Venous Thromboembolism)

## Interventions

- **DRUG:** Apixaban 2.5 mg twice daily
- **DRUG:** Apixaban 5 mg once daily
- **DRUG:** No anticoagulation

## Key facts

- **NCT ID:** NCT07005024
- **Lead sponsor:** University of Vermont
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-17
- **Primary completion:** 2035-08
- **Final completion:** 2035-08
- **Target enrollment:** 996 (ESTIMATED)
- **Last updated:** 2026-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07005024

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07005024, "DOAC - Dosing Options in AntiCoagulation Prophylaxis". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT07005024. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*